{
    "nctId": "NCT06238986",
    "briefTitle": "Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Breast Cancer Receiving Chemotherapy",
    "officialTitle": "Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Breast Cancer Receiving Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Change in GI microbiome profile",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female with a new diagnosis of breast cancer (stage I-III)\n* Age 20 or older\n* Able to read and write in English\n* Chemotherapy naive and beginning the first cycle of moderately or highly emetogenic chemotherapy (For example, Taxotere + cyclophosphamide treatment +/- trastuzumab). Patients who have not received chemotherapy for five years or more are considered chemotherapy naive\n\nExclusion Criteria:\n\n* Metastatic disease\n* Cognitive impairment, based on clinician assessment, that would prevent completing measures\n* Concurrent radiation therapy or radiation therapy within the last three months\n* GI co-morbidities (i.e., irritable bowel syndrome, gastroesophageal reflux disease) or bowel surgery within the last three months\n* A stoma preventing stool collection from the large intestine (i.e., ileostomy)",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}